Inflammatory Disease News and Research

RSS

Alder Biopharmaceuticals reports positive data from ALD518 Phase 2a clinical trial for NSCLC

Alder Biopharmaceuticals Inc. today announced that patients with late-stage non-small cell lung cancer (NSCLC) showed improvement in cancer-related anemia and symptoms of the disease in a Phase 2a clinical trial of ALD518, a monoclonal antibody directed against interleukin-6 (IL-6).

7 Jun 2010

Mayo Clinic research reveals increase in incidence of rheumatoid arthritis in women

The incidence of rheumatoid arthritis (RA) in women has risen during the period of 1995 to 2007, according to a newly published study by researchers from the Mayo Clinic. This rise in RA follows a 4-decade period of decline and study authors speculate environmental factors such as cigarette smoking, vitamin D deficiency, and lower dose synthetic estrogens in oral contraceptives may be the source of the increase.

27 May 2010

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, "HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS," which includes coverage of Amira's AM461 DP2 receptor antagonist.

27 May 2010

Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV

Roche Diagnostics Canada announced today the launch of a new Health Canada approved clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas(R) 4800 System combines in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology.

From Roche Sequencing and Life Science 7 May 2010

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.

7 May 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Roche today announced that Health Canada has approved ACTEMRA(TM) (tocilizumab) to treat patients with rheumatoid arthritis (RA), a chronic, progressive inflammatory disease of the joints and surrounding tissues that is associated with intense pain, irreversible joint destruction and systemic complications, such as fatigue and anemia.

4 May 2010

Johns Hopkins researchers identify a key protein that triggers sarcoidosis

Lung researchers at Johns Hopkins have identified a possible protein trigger responsible for sarcoidosis, a potentially fatal inflammatory disease marked by tiny clumps of inflammatory cells that each year leave deep, grainy scars on the lungs, lymph nodes, skin and almost all major organs in hundreds of thousands of Americans.

4 May 2010

African-Americans less likely to have varus thrust, more likely to have valgus thrust than Caucasians

A recent study determined that African-Americans were less likely to have a varus thrust, but more likely to have valgus thrust than Caucasians. Varus thrust is visualized during gait as the worsening or abrupt onset of varus (bow-legged) alignment as the leg accepts weight, with a return to less varus and more neutral alignment during lift-off of the foot and the swing phase of gait.

3 May 2010

VIMOVO delayed-release tablets receive FDA approval

AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

3 May 2010

Gonorrhea may soon become untreatable according to WHO

According to the World Health organization (WHO), gonorrhea may soon become untreatable and urgent measures need to be taken to prevent and treat the sexually transmitted infection. This is the result of improper use of first line antibiotics which has led to widespread anti microbial resistance to drugs. The cheaper antibiotics no longer have as much effect as they should and the higher antibiotics will soon lose efficacy as well.

30 Apr 2010

Combination of antibiotics can cure Chlamydia-induced ReA: Study

Researchers from University of South Florida College of Medicine found a combination of antibiotics to be an effective treatment for Chlamydia-induced reactive arthritis, a major step forward in the management, and possibly cure, of this disease. Results of this study are published in the May issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

29 Apr 2010

MorphoSys AG reports Q1 results for 2010

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) today announced its financial results for the three months ending March 31, 2010 according to International Financial Reporting Standards (IFRS).

27 Apr 2010

Nitration and allergy

Food proteins are nitrated through various processes. Just how these processes affect food allergies, however, is only now coming to light. The latest findings of a research project funded by the Austrian Science Fund FWF are being presented today at an international symposium in Italy. The findings show that in the case of a particular food protein the nitrated form can trigger a stronger allergic reaction than the non-nitrated form. At the same time, however, this nitrated form of the protein is better digested and therefore rendered "harmless".

27 Apr 2010

Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted it patent number GB2460597 titled "N,N-Disubstituted aminoalkylBiPhenyl Antagonists OF Prostaglandin d2 RECEPTORS."

23 Apr 2010

Dimerix Bioscience announces research agreement with Takeda Cambridge

Dimerix Bioscience Pty Ltd, a pre-clinical stage product company developing a pipeline of 'best in class' lead products with highly specific activity and with reduced risk of off-target effects, today announced that it has entered into a research agreement with Takeda Cambridge Limited, a UK based subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company.

20 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

16 Apr 2010

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

ChemoCentryx, Inc., today announced that it has identified a novel drug candidate targeting the chemoattractant receptor known as ChemR23. This investigational new drug, designated CCX832, is an orally-administered small molecule antagonist of ChemR23, an important player in inflammatory disease.

9 Apr 2010

Women living in northeastern U.S. more likely to develop RA: Study

Women living in the northeastern United States are more likely to develop rheumatoid arthritis, suggesting a link between the autoimmune disease and vitamin D deficiency, says a new study led by a Boston University School of Public Health researcher.

8 Apr 2010

Passengers on Brisbane train may have been exposed to measles

A NSW man who was diagnosed with measles travelled in a train from the Brisbane International Airport to South Brisbane about 8am on Saturday.

2 Apr 2010